LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 36

Search options

  1. Article ; Online: Re-emergence of influenza virus circulation during 2020 in parts of tropical Asia: Implications for other countries.

    Mott, Joshua A / Fry, Alicia M / Kondor, Rebecca / Wentworth, David E / Olsen, Sonja J

    Influenza and other respiratory viruses

    2021  Volume 15, Issue 3, Page(s) 415–418

    MeSH term(s) Asia/epidemiology ; Humans ; Influenza A Virus, H3N2 Subtype ; Influenza, Human/epidemiology
    Language English
    Publishing date 2021-02-10
    Publishing country England
    Document type Letter
    ZDB-ID 2274538-5
    ISSN 1750-2659 ; 1750-2640
    ISSN (online) 1750-2659
    ISSN 1750-2640
    DOI 10.1111/irv.12844
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Genetic and potential antigenic evolution of influenza A(H1N1)pdm09 viruses circulating in Kenya during 2009-2018 influenza seasons.

    Owuor, D Collins / de Laurent, Zaydah R / Nyawanda, Bryan O / Emukule, Gideon O / Kondor, Rebecca / Barnes, John R / Nokes, D James / Agoti, Charles N / Chaves, Sandra S

    Scientific reports

    2023  Volume 13, Issue 1, Page(s) 22342

    Abstract: Influenza viruses undergo rapid evolutionary changes, which requires continuous surveillance to monitor for genetic and potential antigenic changes in circulating viruses that can guide control and prevention decision making. We sequenced and ... ...

    Abstract Influenza viruses undergo rapid evolutionary changes, which requires continuous surveillance to monitor for genetic and potential antigenic changes in circulating viruses that can guide control and prevention decision making. We sequenced and phylogenetically analyzed A(H1N1)pdm09 virus genome sequences obtained from specimens collected from hospitalized patients of all ages with or without pneumonia between 2009 and 2018 from seven sentinel surveillance sites across Kenya. We compared these sequences with recommended vaccine strains during the study period to infer genetic and potential antigenic changes in circulating viruses and associations of clinical outcome. We generated and analyzed a total of 383 A(H1N1)pdm09 virus genome sequences. Phylogenetic analyses of HA protein revealed that multiple genetic groups (clades, subclades, and subgroups) of A(H1N1)pdm09 virus circulated in Kenya over the study period; these evolved away from their vaccine strain, forming clades 7 and 6, subclades 6C, 6B, and 6B.1, and subgroups 6B.1A and 6B.1A1 through acquisition of additional substitutions. Several amino acid substitutions among circulating viruses were associated with continued evolution of the viruses, especially in antigenic epitopes and receptor binding sites (RBS) of circulating viruses. Disease severity declined with an increase in age among children aged < 5 years. Our study highlights the necessity of timely genomic surveillance to monitor the evolutionary changes of influenza viruses. Routine influenza surveillance with broad geographic representation and whole genome sequencing capacity to inform on prioritization of antigenic analysis and the severity of circulating strains are critical to improved selection of influenza strains for inclusion in vaccines.
    MeSH term(s) Child ; Humans ; Influenza, Human/epidemiology ; Influenza A Virus, H1N1 Subtype ; Phylogeny ; Kenya/epidemiology ; Seasons ; Hemagglutinin Glycoproteins, Influenza Virus/genetics ; Influenza Vaccines/genetics
    Chemical Substances Hemagglutinin Glycoproteins, Influenza Virus ; Influenza Vaccines
    Language English
    Publishing date 2023-12-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-49157-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Timing of seasonal influenza epidemics for 25 countries in Africa during 2010-19: a retrospective analysis.

    Igboh, Ledor S / Roguski, Katherine / Marcenac, Perrine / Emukule, Gideon O / Charles, Myrna D / Tempia, Stefano / Herring, Belinda / Vandemaele, Katelijn / Moen, Ann / Olsen, Sonja J / Wentworth, David E / Kondor, Rebecca / Mott, Josh A / Hirve, Siddhivinayak / Bresee, Joseph S / Mangtani, Punam / Nguipdop-Djomo, Patrick / Azziz-Baumgartner, Eduardo

    The Lancet. Global health

    2023  Volume 11, Issue 5, Page(s) e729–e739

    Abstract: Background: Using country-specific surveillance data to describe influenza epidemic activity could inform decisions on the timing of influenza vaccination. We analysed surveillance data from African countries to characterise the timing of seasonal ... ...

    Abstract Background: Using country-specific surveillance data to describe influenza epidemic activity could inform decisions on the timing of influenza vaccination. We analysed surveillance data from African countries to characterise the timing of seasonal influenza epidemics to inform national vaccination strategies.
    Methods: We used publicly available sentinel data from African countries reporting to the WHO Global Influenza Surveillance and Response FluNet platform that had 3-10 years of data collected during 2010-19. We calculated a 3-week moving proportion of samples positive for influenza virus and assessed epidemic timing using an aggregate average method. The start and end of each epidemic were defined as the first week when the proportion of positive samples exceeded or went below the annual mean, respectively, for at least 3 consecutive weeks. We categorised countries into five epidemic patterns: northern hemisphere-dominant, with epidemics occurring in October-March; southern hemisphere-dominant, with epidemics occurring in April-September; primarily northern hemisphere with some epidemic activity in southern hemisphere months; primarily southern hemisphere with some epidemic activity in northern hemisphere months; and year-round influenza transmission without a discernible northern hemisphere or southern hemisphere predominance (no clear pattern).
    Findings: Of the 34 countries reporting data to FluNet, 25 had at least 3 years of data, representing 46% of the countries in Africa and 89% of Africa's population. Study countries reported RT-PCR respiratory virus results for a total of 503 609 specimens (median 12 971 [IQR 9607-20 960] per country-year), of which 74 001 (15%; median 2078 [IQR 1087-3008] per country-year) were positive for influenza viruses. 248 epidemics occurred across 236 country-years of data (median 10 [range 7-10] per country). Six (24%) countries had a northern hemisphere pattern (Algeria, Burkina Faso, Egypt, Morocco, Niger, and Tunisia). Eight (32%) had a primarily northern hemisphere pattern with some southern hemisphere epidemics (Cameroon, Ethiopia, Mali, Mozambique, Nigeria, Senegal, Tanzania, and Togo). Three (12%) had a primarily southern hemisphere pattern with some northern hemisphere epidemics (Ghana, Kenya, and Uganda). Three (12%) had a southern hemisphere pattern (Central African Republic, South Africa, and Zambia). Five (20%) had no clear pattern (Côte d'Ivoire, DR Congo, Madagascar, Mauritius, and Rwanda).
    Interpretation: Most countries had identifiable influenza epidemic periods that could be used to inform authorities of non-seasonal and seasonal influenza activity, guide vaccine timing, and promote timely interventions.
    Funding: None.
    Translations: For the Berber, Luganda, Xhosa, Chewa, Yoruba, Igbo, Hausa and Afan Oromo translations of the abstract see Supplementary Materials section.
    MeSH term(s) Humans ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Retrospective Studies ; Influenza Vaccines ; Epidemics ; Burkina Faso ; Seasons
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2023-04-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2723488-5
    ISSN 2214-109X ; 2214-109X
    ISSN (online) 2214-109X
    ISSN 2214-109X
    DOI 10.1016/S2214-109X(23)00109-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Targeted amplification and genetic sequencing of the severe acute respiratory syndrome coronavirus 2 surface glycoprotein.

    Keller, Matthew W / Keong, Lisa M / Rambo-Martin, Benjamin L / Hassell, Norman / Lacek, Kristine A / Wilson, Malania M / Kirby, Marie K / Liddell, Jimma / Owuor, D Collins / Sheth, Mili / Madden, Joseph / Lee, Justin S / Kondor, Rebecca J / Wentworth, David E / Barnes, John R

    Microbiology spectrum

    2023  Volume 12, Issue 1, Page(s) e0298223

    Abstract: Importance: The COVID-19 pandemic was accompanied by an unprecedented surveillance effort. The resulting data were and will continue to be critical for surveillance and control of SARS-CoV-2. However, some genomic surveillance methods experienced ... ...

    Abstract Importance: The COVID-19 pandemic was accompanied by an unprecedented surveillance effort. The resulting data were and will continue to be critical for surveillance and control of SARS-CoV-2. However, some genomic surveillance methods experienced challenges as the virus evolved, resulting in incomplete and poor quality data. Complete and quality coverage, especially of the S-gene, is important for supporting the selection of vaccine candidates. As such, we developed a robust method to target the S-gene for amplification and sequencing. By focusing on the S-gene and imposing strict coverage and quality metrics, we hope to increase the quality of surveillance data for this continually evolving gene. Our technique is currently being deployed globally to partner laboratories, and public health representatives from 79 countries have received hands-on training and support. Expanding access to quality surveillance methods will undoubtedly lead to earlier detection of novel variants and better inform vaccine strain selection.
    MeSH term(s) Humans ; SARS-CoV-2/genetics ; COVID-19/epidemiology ; Pandemics ; Membrane Glycoproteins ; Vaccines
    Chemical Substances Membrane Glycoproteins ; Vaccines
    Language English
    Publishing date 2023-12-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2807133-5
    ISSN 2165-0497 ; 2165-0497
    ISSN (online) 2165-0497
    ISSN 2165-0497
    DOI 10.1128/spectrum.02982-23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages.

    Xia, Hongjie / Yeung, Jason / Kalveram, Birte / Bills, Cody J / Chen, John Yun-Chung / Kurhade, Chaitanya / Zou, Jing / Widen, Steven G / Mann, Brian R / Kondor, Rebecca / Davis, C Todd / Zhou, Bin / Wentworth, David E / Xie, Xuping / Shi, Pei-Yong

    Emerging microbes & infections

    2023  Volume 12, Issue 1, Page(s) e2161422

    Abstract: The rapid evolution of SARS-CoV-2 Omicron sublineages mandates a better understanding of viral replication and cross-neutralization among these sublineages. Here we used K18-hACE2 mice and primary human airway cultures to examine the viral fitness and ... ...

    Abstract The rapid evolution of SARS-CoV-2 Omicron sublineages mandates a better understanding of viral replication and cross-neutralization among these sublineages. Here we used K18-hACE2 mice and primary human airway cultures to examine the viral fitness and antigenic relationship among Omicron sublineages. In both K18-hACE2 mice and human airway cultures, Omicron sublineages exhibited a replication order of BA.5 ≥ BA.2 ≥ BA.2.12.1 > BA.1; no difference in body weight loss was observed among different sublineage-infected mice. The BA.1-, BA.2-, BA.2.12.1-, and BA.5-infected mice developed distinguishable cross-neutralizations against Omicron sublineages, but exhibited little neutralization against the index virus (i.e. USA-WA1/2020) or the Delta variant. Surprisingly, the BA.5-infected mice developed higher neutralization activity against heterologous BA.2 and BA.2.12.1 than that against homologous BA.5; serum neutralizing titres did not always correlate with viral replication levels in infected animals. Our results revealed a distinct antigenic cartography of Omicron sublineages and support the bivalent vaccine approach.
    MeSH term(s) Humans ; Animals ; Mice ; SARS-CoV-2/genetics ; COVID-19 ; Melphalan ; Antibodies, Viral ; Antibodies, Neutralizing
    Chemical Substances K-18 conjugate ; Melphalan (Q41OR9510P) ; Antibodies, Viral ; Antibodies, Neutralizing
    Language English
    Publishing date 2023-01-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2681359-2
    ISSN 2222-1751 ; 2222-1751
    ISSN (online) 2222-1751
    ISSN 2222-1751
    DOI 10.1080/22221751.2022.2161422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Spike Gene Target Amplification in a Diagnostic Assay as a Marker for Public Health Monitoring of Emerging SARS-CoV-2 Variants - United States, November 2021-January 2023.

    Scobie, Heather M / Ali, Akilah R / Shirk, Philip / Smith, Zachary R / Paul, Prabasaj / Paden, Clinton R / Hassell, Norman / Zheng, Xiao-Yu / Lambrou, Anastasia S / Kondor, Rebecca / MacCannell, Duncan / Thornburg, Natalie J / Miller, Joseph / Wentworth, Dave / Silk, Benjamin J

    MMWR. Morbidity and mortality weekly report

    2023  Volume 72, Issue 5, Page(s) 125–127

    Abstract: Monitoring emerging SARS-CoV-2 lineages and their epidemiologic characteristics helps to inform public health decisions regarding vaccine policy, the use of therapeutics, and health care capacity. When the SARS-CoV-2 Alpha variant emerged in late 2020, a ...

    Abstract Monitoring emerging SARS-CoV-2 lineages and their epidemiologic characteristics helps to inform public health decisions regarding vaccine policy, the use of therapeutics, and health care capacity. When the SARS-CoV-2 Alpha variant emerged in late 2020, a spike gene (S-gene) deletion (Δ69-70) in the N-terminal region, which might compensate for immune escape mutations that impair infectivity (1), resulted in reduced or failed S-gene target amplification in certain multitarget reverse transcription-polymerase chain reaction (RT-PCR) assays, a pattern referred to as S-gene target failure (SGTF) (2). The predominant U.S. SARS-CoV-2 lineages have generally alternated between SGTF and S-gene target presence (SGTP), which alongside genomic sequencing, has facilitated early monitoring of emerging variants. During a period when Omicron BA.5-related sublineages (which exhibit SGTF) predominated, an XBB.1.5 sublineage with SGTP has rapidly expanded in the northeastern United States and other regions.
    MeSH term(s) United States/epidemiology ; Humans ; Public Health ; SARS-CoV-2/genetics ; COVID-19/epidemiology ; Mutation ; COVID-19 Testing
    Language English
    Publishing date 2023-02-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 412775-4
    ISSN 1545-861X ; 0149-2195
    ISSN (online) 1545-861X
    ISSN 0149-2195
    DOI 10.15585/mmwr.mm7205e2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.

    Patel, Mira C / Flanigan, Daniel / Feng, Chenchen / Chesnokov, Anton / Nguyen, Ha T / Elal, Anwar Abd / Steel, John / Kondor, Rebecca J / Wentworth, David E / Gubareva, Larisa V / Mishin, Vasiliy P

    Antiviral research

    2022  Volume 208, Page(s) 105457

    Abstract: Year-round virological characterization of circulating epidemic influenza viruses is conducted worldwide to detect the emergence of viruses that may escape pre-existing immunity or acquire resistance to antivirals. High throughput phenotypic assays are ... ...

    Abstract Year-round virological characterization of circulating epidemic influenza viruses is conducted worldwide to detect the emergence of viruses that may escape pre-existing immunity or acquire resistance to antivirals. High throughput phenotypic assays are needed to complement the sequence-based analysis of circulating viruses and improve pandemic preparedness. The recent entry of a polymerase inhibitor, baloxavir, into the global market further highlighted this need. Here, we optimized a cell-based assay that considerably streamlines antiviral and antigenic testing by replacing lengthy immunostaining and imaging procedures used in current assay with measuring the enzymatic activity of nascent neuraminidase (NA) molecules expressed on the surface of virus-infected cells. For convenience, this new assay was named IRINA (Influenza Replication Inhibition Neuraminidase-based Assay). IRINA was successfully validated to assess inhibitory activity of baloxavir on virus replication by testing a large set (>150) of influenza A and B viruses, including drug resistant strains and viruses collected during 2017-2022. To test its versatility, IRINA was utilized to evaluate neutralization activity of a broadly reactive human anti-HA monoclonal antibody, FI6, and post-infection ferret antisera, as well as the inhibition of NA enzyme activity by NA inhibitors. Performance of IRINA was tested in parallel using respective conventional assays. IRINA offers an attractive alternative to current phenotypic assays, while maintaining reproducibility and high throughput capacity. Additionally, the improved turnaround time may prove to be advantageous when conducting time sensitive studies, such as investigating a new virus outbreak. This assay can meet the needs of surveillance laboratories by providing a streamlined and cost-effective approach for virus characterization.
    MeSH term(s) Animals ; Humans ; Neuraminidase ; Influenza, Human ; Reproducibility of Results ; Drug Resistance, Viral ; Ferrets ; Virus Replication ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Enzyme Inhibitors/pharmacology ; Oseltamivir/pharmacology
    Chemical Substances Neuraminidase (EC 3.2.1.18) ; baloxavir (4G86Y4JT3F) ; Antiviral Agents ; Enzyme Inhibitors ; Oseltamivir (20O93L6F9H)
    Language English
    Publishing date 2022-11-01
    Publishing country Netherlands
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2022.105457
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Antigenic drift and subtype interference shape A(H3N2) epidemic dynamics in the United States.

    Perofsky, Amanda C / Huddleston, John / Hansen, Chelsea / Barnes, John R / Rowe, Thomas / Xu, Xiyan / Kondor, Rebecca / Wentworth, David E / Lewis, Nicola / Whittaker, Lynne / Ermetal, Burcu / Harvey, Ruth / Galiano, Monica / Daniels, Rodney Stuart / McCauley, John W / Fujisaki, Seiichiro / Nakamura, Kazuya / Kishida, Noriko / Watanabe, Shinji /
    Hasegawa, Hideki / Sullivan, Sheena G / Barr, Ian G / Subbarao, Kanta / Krammer, Florian / Bedford, Trevor / Viboud, Cécile

    medRxiv : the preprint server for health sciences

    2023  

    Abstract: Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the ...

    Abstract Influenza viruses continually evolve new antigenic variants, through mutations in epitopes of their major surface proteins, hemagglutinin (HA) and neuraminidase (NA). Antigenic drift potentiates the reinfection of previously infected individuals, but the contribution of this process to variability in annual epidemics is not well understood. Here we link influenza A(H3N2) virus evolution to regional epidemic dynamics in the United States during 1997-2019. We integrate phenotypic measures of HA antigenic drift and sequence-based measures of HA and NA fitness to infer antigenic and genetic distances between viruses circulating in successive seasons. We estimate the magnitude, severity, timing, transmission rate, age-specific patterns, and subtype dominance of each regional outbreak and find that genetic distance based on broad sets of epitope sites is the strongest evolutionary predictor of A(H3N2) virus epidemiology. Increased HA and NA epitope distance between seasons correlates with larger, more intense epidemics, higher transmission, greater A(H3N2) subtype dominance, and a greater proportion of cases in adults relative to children, consistent with increased population susceptibility. Based on random forest models, A(H1N1) incidence impacts A(H3N2) epidemics to a greater extent than viral evolution, suggesting that subtype interference is a major driver of influenza A virus infection dynamics, presumably via heterosubtypic cross-immunity.
    Language English
    Publishing date 2023-10-03
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.10.02.23296453
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Targeted Amplification and Genetic Sequencing of the Severe Acute Respiratory Syndrome Coronavirus 2 Surface Glycoprotein

    Keller, Matthew W. / Keong, Lisa M. / Rambo-Martin, Benjamin L. / Hassell, Norman / Lacek, Kristine / Wilson, Malania M. / Kirby, Marie K. / Liddell, Jimma / Owuor, D. Collins / Sheth, Mili / Madden, Joseph / Lee, Justin S. / Kondor, Rebecca J. / Wentworth, David E. / Barnes, John R.

    bioRxiv

    Abstract: The SARS-CoV-2 spike protein is a highly immunogenic and mutable protein that is the target of vaccine prevention and antibody therapeutics. This makes the encoding S-gene an important sequencing target. The SARS-CoV-2 sequencing community overwhelmingly ...

    Abstract The SARS-CoV-2 spike protein is a highly immunogenic and mutable protein that is the target of vaccine prevention and antibody therapeutics. This makes the encoding S-gene an important sequencing target. The SARS-CoV-2 sequencing community overwhelmingly adopted tiling amplicon-based strategies for sequencing the entire genome. As the virus evolved, primer mismatches inevitably led to amplicon drop-out. Given the exposure of the spike protein to host antibodies, mutation occurred here most rapidly, leading to amplicon failure over the most insightful region of the genome. To mitigate this, we developed SpikeSeq, a targeted method to amplify and sequence the S-gene. We evaluated 20 distinct primer designs through iterative in silico and in vitro testing to select the optimal primer pairs and run conditions. Once selected, periodic in silico analysis monitor primer conservation as SARS-CoV-2 evolves. Despite being designed during the Beta wave, the selected primers remain > 99% conserved through Omicron as of 2023-04-14. To validate the final design, we compared SpikeSeq data and National SARS-CoV-2 Strain Surveillance whole-genome data for 321 matching samples. Consensus sequences for the two methods were highly identical (99.998%) across the S-gene. SpikeSeq can serve as a complement to whole-genome surveillance or be leveraged where only S-gene sequencing is of interest. While SpikeSeq is adaptable to other sequencing platforms, the Nanopore platform validated here is compatible with low to moderate throughputs, and its simplicity better enables users to achieve accurate results, even in low resource settings.
    Keywords covid19
    Language English
    Publishing date 2023-08-01
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2023.07.28.551051
    Database COVID19

    Kategorien

  10. Article ; Online: Detection of baloxavir resistant influenza A viruses using next generation sequencing and pyrosequencing methods.

    Patel, Mira C / Mishin, Vasiliy P / De La Cruz, Juan A / Chesnokov, Anton / Nguyen, Ha T / Wilson, Malania M / Barnes, John / Kondor, Rebecca J G / Wentworth, David E / Gubareva, Larisa V

    Antiviral research

    2020  Volume 182, Page(s) 104906

    Abstract: Baloxavir, a new antiviral drug targeting cap-dependent endonuclease activity of polymerase acidic (PA) protein of influenza viruses, is now approved in multiple countries. Several substitutions at isoleucine 38 in PA protein (e.g., PA-I38T) have been ... ...

    Abstract Baloxavir, a new antiviral drug targeting cap-dependent endonuclease activity of polymerase acidic (PA) protein of influenza viruses, is now approved in multiple countries. Several substitutions at isoleucine 38 in PA protein (e.g., PA-I38T) have been associated with decreased baloxavir susceptibility in vitro and in vivo. In recent years, next generation sequencing (NGS) analysis and pyrosequencing have been used by CDC and U.S. Public Health Laboratories to monitor drug susceptibility of influenza viruses. Here we described an improved pyrosequencing assay for detecting influenza A viruses carrying substitutions at PA-38. Cyclic and customized orders of nucleotide dispensation were evaluated, and pyrosequencing results were compared to those generated using NGS. Our data showed that the customized nucleotide dispensation has improved the pyrosequencing assay performance in identification of double mixtures (e.g., PA-38I/T); however, identification of PA-38 variants in triple mixtures remains a challenge. While NGS analysis indicated the presence of PA-I38K in one clinical specimen and isolate, our attempts to detect this mutation by pyrosequencing or recover the virus carrying PA-I38K in cell culture were unsuccessful, raising a possibility of a rarely occurring sequencing error. Overall, pyrosequencing provides a convenient means to detect baloxavir resistant influenza viruses when NGS is unavailable or a faster turnaround time is required.
    Keywords covid19
    Language English
    Publishing date 2020-08-14
    Publishing country Netherlands
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2020.104906
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top